Latest Insider Transactions at Epizyme, Inc. (EPZM)
This section provides a real-time view of insider transactions for Epizyme, Inc. (EPZM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Epizyme, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Epizyme, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 12
2022
|
Michael F Giordano Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,054
-73.63%
|
-
|
|
Aug 12
2022
|
Carl Goldfischer Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,380,951
-100.0%
|
-
|
|
Aug 12
2022
|
Carl Goldfischer Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,054
-79.61%
|
-
|
|
Aug 12
2022
|
Victoria Richon Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,608
-80.11%
|
-
|
|
Aug 12
2022
|
David M Mott Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
106,959
-100.0%
|
-
|
|
Aug 12
2022
|
David M Mott Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
8,994
-100.0%
|
-
|
|
Aug 12
2022
|
David M Mott Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
215,494
-95.99%
|
-
|
|
Aug 12
2022
|
Legorreta Pablo G. Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
31,933,334
-100.0%
|
-
|
|
Aug 12
2022
|
Jeffery Kutok Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
120,067
-66.26%
|
-
|
|
Aug 12
2022
|
Carol Stuckley Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
25,696
-100.0%
|
-
|
|
Aug 12
2022
|
Kevin T Conroy Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
62,318
-92.78%
|
-
|
|
Aug 12
2022
|
Grant C. Bogle President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
259,170
-66.24%
|
-
|
|
Aug 12
2022
|
Joseph Beaulieu Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
52,076
-78.98%
|
-
|
|
Aug 12
2022
|
Beveridge, Roy A Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
46,037
-72.09%
|
-
|
|
Aug 12
2022
|
Kenneth Bate Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,054
-73.63%
|
-
|
|
Aug 12
2022
|
Shefali Agarwal |
SELL
Sale (or disposition) back to the issuer
|
Direct |
286,539
-81.28%
|
-
|
|
Aug 09
2022
|
Jeffery Kutok Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
354,496
-74.7%
|
$354,496
$1.39 P/Share
|
|
Aug 09
2022
|
Jeffery Kutok Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
380,000
+44.47%
|
$380,000
$1.39 P/Share
|
|
Aug 09
2022
|
Grant C. Bogle President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,141,390
-68.15%
|
$1,141,390
$1.4 P/Share
|
|
Aug 09
2022
|
Grant C. Bogle President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,217,500
+41.91%
|
$1,217,500
$1.4 P/Share
|
|
Aug 09
2022
|
Joseph Beaulieu Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
279,864
-84.56%
|
$279,864
$1.39 P/Share
|
|
Aug 09
2022
|
Joseph Beaulieu Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300,000
+47.55%
|
$300,000
$1.39 P/Share
|
|
Aug 09
2022
|
Shefali Agarwal |
SELL
Payment of exercise price or tax liability
|
Direct |
373,154
-56.65%
|
$373,154
$1.39 P/Share
|
|
Aug 09
2022
|
Shefali Agarwal |
BUY
Exercise of conversion of derivative security
|
Direct |
500,000
+24.32%
|
$500,000
$1.39 P/Share
|
|
Jun 30
2022
|
David M Mott Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,156
+6.71%
|
$16,156
$1.47 P/Share
|
|
Jun 30
2022
|
Kevin T Conroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,204
+14.07%
|
$10,204
$1.47 P/Share
|
|
Jun 30
2022
|
Beveridge, Roy A Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,928
+16.24%
|
$8,928
$1.47 P/Share
|
|
May 17
2022
|
Beveridge, Roy A Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,994
+19.51%
|
-
|
|
May 17
2022
|
Carl Goldfischer Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,994
+28.97%
|
-
|
|
May 17
2022
|
Kevin T Conroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,994
+14.72%
|
-
|
|
May 17
2022
|
David M Mott Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,994
+4.14%
|
-
|
|
May 17
2022
|
Michael F Giordano Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,994
+34.53%
|
-
|
|
May 17
2022
|
Carol Stuckley Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,994
+25.93%
|
-
|
|
May 17
2022
|
Victoria Richon Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,994
+28.46%
|
-
|
|
May 17
2022
|
Kenneth Bate Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,994
+34.53%
|
-
|
|
Apr 11
2022
|
Jeffery Kutok Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,741
-2.82%
|
$0
$0.9 P/Share
|
|
Mar 31
2022
|
Kevin T Conroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,043
+23.22%
|
$13,043
$1.15 P/Share
|
|
Mar 31
2022
|
David M Mott Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,653
+9.39%
|
$20,653
$1.15 P/Share
|
|
Mar 31
2022
|
Beveridge, Roy A Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,413
+28.87%
|
$11,413
$1.15 P/Share
|
|
Feb 28
2022
|
Shefali Agarwal |
BUY
Grant, award, or other acquisition
|
Direct |
2,331
+1.45%
|
$2,331
$1.27 P/Share
|
|
Feb 28
2022
|
Joseph Beaulieu Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,331
+7.0%
|
$2,331
$1.27 P/Share
|
|
Feb 07
2022
|
Shefali Agarwal |
SELL
Open market or private sale
|
Direct |
1,058
-0.67%
|
$1,058
$1.5 P/Share
|
|
Feb 07
2022
|
Joseph Beaulieu Officer |
SELL
Open market or private sale
|
Direct |
222
-0.77%
|
$222
$1.5 P/Share
|
|
Feb 02
2022
|
Joseph Beaulieu Officer |
SELL
Open market or private sale
|
Direct |
687
-2.33%
|
$687
$1.37 P/Share
|
|
Feb 02
2022
|
Jeffery Kutok Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,556
-2.56%
|
$2,556
$1.37 P/Share
|
|
Feb 02
2022
|
Grant C. Bogle President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+32.34%
|
-
|
|
Feb 02
2022
|
Shefali Agarwal |
SELL
Open market or private sale
|
Direct |
2,639
-1.65%
|
$2,639
$1.37 P/Share
|
|
Jan 31
2022
|
Legorreta Pablo G. Director |
BUY
Open market or private purchase
|
Indirect |
22,666,667
+41.59%
|
$22,666,667
$1.5 P/Share
|
|
Jan 26
2022
|
Shefali Agarwal |
SELL
Open market or private sale
|
Direct |
2,922
-1.79%
|
$5,844
$2.02 P/Share
|
|
Dec 31
2021
|
Kevin T Conroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,000
+16.63%
|
$12,000
$2.5 P/Share
|